Focuses on the development of therapies for cancer treatment, targeting the cell cycle and DNA damage response pathways to inhibit tumor growth.
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing small molecule therapeutics for cancer treatment. Central to its portfolio is COSELA, designed to mitigate chemotherapy-induced myelosuppression in adult patients undergoing platinum/etoposide or topotecan regimens for extensive stage small cell lung cancer. The company is also progressing trilaciclib, a CDK 4/6 inhibitor currently in Phase III trials across multiple fronts, including first line colorectal cancer, triple negative breast cancer, bladder cancer in combination with antibody-drug conjugates, and neoadjuvant breast cancer.
Further expanding its pipeline, G1 Therapeutics is developing lerociclib, an oral CDK4/6 inhibitor targeting various oncology indications. Additionally, the company is advancing rintodestrant, an oral selective estrogen receptor degrader, through Phase IIa clinical trials for estrogen receptor-positive and HER2-negative breast cancer. G1 Therapeutics has established strategic partnerships to enhance its drug development efforts, including agreements with EQRx, Inc., Genor Biopharma Co. Inc., Nanjing Simcere Dongyuan Pharmaceutical Co., LTD., and ARC Therapeutics, aimed at advancing treatments like lerociclib and trilaciclib through different delivery methods.
Founded in 2008 and headquartered in Research Triangle Park, North Carolina, G1 Therapeutics, Inc. continues to innovate in oncology therapeutics, striving to improve outcomes for cancer patients through its robust clinical pipeline and strategic collaborations.